Ufonia uses artificial intelligence to develop automated clinical-grade conversations, capable of replacing routine medical appointments.
Funding stage: Seed
The investment teams managing the Fund have made investments in some revolutionary early-stage knowledge intensive companies, which are already changing the way we shop, live and work. Here’s a key example.
What is it?
Ufonia uses artificial intelligence (AI) to develop automated clinical-grade conversations, capable of replacing routine medical appointments, and integrating into health systems. This aims to increase patient engagement and free up more time for medical staff to focus on patients that need the most attention.
Ufonia calls a patient’s phone at a pre-agreed time, for an automated and adaptive voice to take them through a series of AI-led health questions, flagging issues to healthcare professionals. It can automatically contact thousands of patients simultaneously, significantly increasing the efficiency of care.
Why we like it
The use of conversational AI is set to grow rapidly in the coming years and the automation market in clinical environments is a multi-billion-pound industry. Clinical trials have shown automated calling achieved high patient acceptability and the platform can be easily integrated with existing health systems, workflows and medical records. It is already achieving significant traction within the NHS – impressive for a company at this stage – and there is a clear opportunity for it to grow nationally and to expand into international markets, with interest from the US already.
More companies we’ve backed
Raylo is a company that aims to transform the way people access, use, and reuse consumer electronics.
A unique blood-based diagnostic test for the earliest possible detection of cancer and genetic mutations.